Use of adcc-optimized antibodies for treating weak patients
AssigneeLaboratoire Francais Du Fractionnement Et Des Biotechnologies
InventorsDominique Bourel, Sylvie Jorieux, Christophe de Romeuf, Philippe Klein, Christine Gaucher, Nicolas Bihoreau, Emmanuel Nony
Life of this patent
Estimating the term…
Abstract
The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
Claims16
1-15. (canceled)
A method for treating haemolytic disease of the newborn, Sezary Syndrome, chronic myeloid leukaemias, chronic lymphoid leukaemias (CLL-B), cancer, breast cancer, conditions related to the environment, infectious diseases, chronic fatigue syndrome (CFS), parasitic infections, or viral infections, comprising:
- administering a composition of antibodies specific to the condition to be treated,
- to a patient homozygous for phenylalanine in position 158 of CD 16 (FCGR3A-158F homozygotes) or heterozygous for valine/phenylalanine in position 158 of CD16 (FCGR3A-158V/F),
- wherein said antibodies are biantennary type,
- wherein said antibodies have an ADCC level via CD16 (FcgammaRIIIa) above 60% compared with the same antibody produced in a CHO line.
Dependencies are inferred from the claim text.